PTX-100's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for PTX-100. Showing past 6 months and next 12 months · 12 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| PTX-100 | Prescient Therapeutics | Small Molecule Other | Phase 2 | 0 | ||||
| A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy | Kyowa Kirin China Pharmaceutical Co., Ltd. | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL | Soligenix | — | Phase 3 | — | — | — | — | — |
| TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides | Assistance Publique - Hôpitaux de Paris | — | Phase 3 | — | — | — | — | — |
| Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance | Assistance Publique - Hôpitaux de Paris | — | Phase 3 | — | — | — | — | — |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | National Cancer Institute (NCI) | — | PHASE2/PHASE3 | — | — | — | — | — |
| Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders | City of Hope Medical Center | — | Phase 2 | — | — | — | — | — |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas | National Cancer Institute (NCI) | — | Phase 2 | — | — | — | — | — |
| A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) | University College, London | — | Phase 2 | — | — | — | — | — |
| IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma | Innate Pharma | — | Phase 2 | — | — | — | — | — |
| Mogamulizumab Q4week Dosing in Participants With R/R CTCL | Kyowa Kirin, Inc. | — | Phase 2 | — | — | — | — | — |
| Photopheresis in Early-stage Mycosis Fungoides | Columbia University | — | Phase 2 | — | — | — | — | — |
| Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas | University of Michigan Rogel Cancer Center | — | Phase 2 | — | — | — | — | — |
| A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma | Chengdu Zenitar Biomedical Technology Co., Ltd | — | Phase 2 | — | — | — | — | — |
| Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | — | Phase 2 | — | — | — | — | — |
| Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma | Northwestern University | — | Phase 2 | — | — | — | — | — |
| A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA | M.D. Anderson Cancer Center | — | Phase 2 | — | — | — | — | — |
| Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma | Yale University | — | Phase 2 | — | — | — | — | — |
| JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas | Institute of Hematology & Blood Diseases Hospital, China | — | Phase 2 | — | — | — | — | — |
| Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome | Stanford University | — | Phase 2 | — | — | — | — | — |
| Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma | David Bond, MD | — | Phase 2 | — | — | — | — | — |
| Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma | Jonathan Brammer | — | Phase 2 | — | — | — | — | — |
| Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides | M.D. Anderson Cancer Center | — | Phase 2 | — | — | — | — | — |
| Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy | Mayo Clinic | — | Phase 2 | — | — | — | — | — |
| Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome | Memorial Sloan Kettering Cancer Center | — | Phase 2 | — | — | — | — | — |
| Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients | Memorial Sloan Kettering Cancer Center | — | Phase 2 | — | — | — | — | — |
| TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Mayo Clinic | — | Phase 2 | — | — | — | — | — |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | National Cancer Institute (NCI) | — | Phase 2 | — | — | — | — | — |
| Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides | M.D. Anderson Cancer Center | — | Phase 2 | — | — | — | — | — |
| Amping up With PemJAK | Seda S. Tolu | — | Phase 2 | — | — | — | — | — |
| A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL | Prescient Therapeutics, Ltd. | — | Phase 2 | — | — | — | — | — |
| SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) | M.D. Anderson Cancer Center | — | Phase 2 | — | — | — | — | — |
| Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma | Yale University | — | Phase 2 | — | — | — | — | — |
| Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma | City of Hope Medical Center | — | Phase 2 | — | — | — | — | — |
| A Study of VG712 in Patients With Mycosis Fungoides | Virogen Biotechnology Inc. | — | Phase 2 | — | — | — | — | — |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | City of Hope Medical Center | — | PHASE1/PHASE2 | — | — | — | — | — |
| CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas | Beijing GoBroad Hospital | — | PHASE1/PHASE2 | — | — | — | — | — |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies | Ossium Health, Inc. | — | PHASE1/PHASE2 | — | — | — | — | — |
| CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas | Beijing GoBroad Hospital | — | PHASE1/PHASE2 | — | — | — | — | — |
| Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma | City of Hope Medical Center | — | PHASE1/PHASE2 | — | — | — | — | — |
| A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | Dren Bio | — | PHASE1/PHASE2 | — | — | — | — | — |
| A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) | Bristol-Myers Squibb | — | PHASE1/PHASE2 | — | — | — | — | — |
| Study of Pembrolizumab (MK-3475) in Combination With Romidepsin | M.D. Anderson Cancer Center | — | PHASE1/PHASE2 | — | — | — | — | — |
| Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma | Shanghai Jiao Tong University School of Medicine | — | PHASE1/PHASE2 | — | — | — | — | — |
| Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | Jonsson Comprehensive Cancer Center | — | PHASE1/PHASE2 | — | — | — | — | — |